RESEARCH STUDY OF ADOLESCENT SCHIZOPHRENIA
UNDERWAY AT NEW YORK UNIVERSITY MEDICAL CENTER – BELLEVUE HOSPITAL

Adolescents with Schizophrenia May Be Eligible to Enroll

(New York City) – The New York University Medical Center – Bellevue Hospital at 462 First Avenue, New York, NY is one of the Clinical trial sites in a nationwide research study evaluating the safety and effectiveness of an atypical antipsychotic medication in adolescents.

“Atypical antipsychotic medications have demonstrated effectiveness and are now widely prescribed for adults, but there has been little research examining the use of these medications in a pediatric population,” said Dr. James C.-Y. Chou, Associate Professor of Psychiatry at NYU-Bellevue. “This trial will provide important data for clinicians when examining treatment options for adolescents with schizophrenia.”

The eight-week study is open to males and females between 13 and 17 years of age who meet the study’s eligibility requirements. All pediatric patients enrolled will receive the study medication; two different dosing regimens will be evaluated. Participants must be inpatients at the time of enrollment and may be eligible to enroll in an open-label extension trial lasting up to 12 months. The permission and support of a parent or legal guardian, and assent of the child, is required throughout the study. The same responsible adult must be available during clinic visits.

For more information about the study or how to refer a patient, please contact Nancy Richardson at (212) 263-6203 during the hours of 9:00 AM to 5:00 PM.

Study of Risk of Agranulocytosis
Genaissance Pharmaceuticals is conducting a research study to discover genetic markers for identifying patients at risk for clozapine-induced agranulocytosis, a potenially life-threatening depletion of white blood cells. Participants must have taken clozapine in the past and developed agranulocytosis. Participants will be asked to provide information about their ethnicity and history of clozapine use. Participants will be asked to give one blood sample equivalent to eight teaspoons.

For more information please call 1-866-812-3700. All contacts will be kept confidential. Individuals will be directed to one of the 40 medical research centers that are conducting this study.

NIMH Gentic Study of Schizophrenia
The scientists at the National Institute of Mental Health believe that environmental factors combined with genetic predisposition lead to the development of schizophrenia. The NIMH genetic studies focus on gathering families' genetic and environmental information to better understand what places one family member at risk and conversely, what protects other family members. To this end, family members are asked to participate in a number of procedures that help scientists measure various family characteristics to see if they run in families. Genotyping, or DNA analysis, is an important part of this process. However, families should understand that this is a very complex analysis and NIMH does not plan to provide family members with individual genetic test results.

The scientists believe that future treatments and preventive methods will rely heavily on the findings of this developing study. It is for this reason that they ask families to participate. Hundreds of families are needed. The staff at NIMH invites you and your family to review this website and welcome you to call for more information: http://cbdb.nimh.nih.gov/sibstudy

For over 40 years, the Schizophrenia Research Program of the National Institute of Mental Health (NIMH) has been a preeminent center for advanced neuroscience research on the causes and treatment of schizophrenia. Located at the National Institutes of Health in Bethesda, Maryland, the program has established a tradition of combining excellent treatment, compassionate care, expert evaluation, and state-of-the-art research.

INPATIENT SCHIZOPHRENIA RESEARCH PROGRAM
For more than 40 years, the Shizophrenia Research Program of the National Institute of Mental Health (NIMH) has been a preeminent center for advanced neuroscience research on the causes and treatment of schizophrenia. Located at the National Institutes of Health in Bethesda, Maryland, the program has established a tradition of combining excellent treatment, compassionate care, expert evaluation, and state-of-the-art research. Please review this for information on the inpatient Schizophrenia Research Program: http://cbdb.nimh.nih.gov/inpatient

University of Iowa Family Study of Manic-depressive Illness
Participants invited to join University of Iowa family study of manic-depressive illness.

Individuals who have manic-depressive illness and who also have a brother or sister with this condition are invited to participate in a family study of manic-depressive illness at the University of Iowa College of Medicine. Manic-depressive illness is also called bipolar disorder.

The study is part of a larger project funded by the NIMH. The project’s goal is to identify the genes that predispose individuals to develop manic-depressive illness. This study may ultimately lead to earlier detection and improved treatment for this disorder.

For more information on participating in this research project, please contact at our toll free number 1 (888) 850-8531. No travel required. Compensation will be provided.